Edition:
United States

Tigenix NV (G9U.BR)

G9U.BR on Brussels Stock Exchange

1.00EUR
11:04am EST
Change (% chg)

€-0.04 (-3.57%)
Prev Close
€1.04
Open
€1.04
Day's High
€1.04
Day's Low
€0.84
Volume
6,332,943
Avg. Vol
722,538
52-wk High
€1.14
52-wk Low
€0.64

Latest Key Developments (Source: Significant Developments)

JP Morgan Chase & Co notifies 3.12 pct shareholding in Tigenix​
Friday, 24 Nov 2017 08:32pm EST 

Nov 24 (Reuters) - Tigenix Nv :‍JP Morgan Chase & Co notifies 3.12 pct shareholding in Tigenix​.  Full Article

Tigenix announces partial conversion of bonds
Monday, 6 Nov 2017 01:00am EST 

Nov 6 (Reuters) - TIGENIX NV : :‍ANNOUNCES CONVERSION OF EUR 7 MILLION OF COMPANY'S SENIOR UNSECURED CONVERTIBLE BONDS DUE 2018​.‍THROUGH CONVERSION, TOTAL CONVERTIBLE DEBT OUTSTANDING REDUCED FROM EUR 25 MILLION TO EUR 18 MILLION​.‍TO ISSUE 7,792,496 SHARES IN EXCHANGE FOR THE CONVERTED BONDS​.‍SHARE EXPECTED TO BE ISSUED ON OR AROUND 10 NOVEMBER 2017​.  Full Article

Tigenix obtains patent for Cx601 lead development program
Thursday, 2 Nov 2017 02:00am EDT 

Nov 2 (Reuters) - TIGENIX NV ::REG-TIGENIX STRENGTHENS EUROPEAN IP PROTECTION AROUND LEAD DEVELOPMENT PROGRAM CX601.‍THIS PATENT PROTECTION GRANTS PRODUCT 10 YEARS OF MARKET EXCLUSIVITY FOLLOWING MARKETING APPROVAL IN EUROPE​.‍SUBMITTED A MARKETING AUTHORIZATION (MA) APPLICATION TO EMA, WHEREFORE A CHMP OPINION IS EXPECTED TO BE RECEIVED IN 2017​.  Full Article

TiGenix provides update on Cx601 marketing authorization application
Tuesday, 31 Oct 2017 02:01am EDT 

Oct 31 (Reuters) - TIGENIX NV ::REG-TIGENIX PROVIDES REGULATORY UPDATE ON CX601 EU MARKETING AUTHORIZATION APPLICATION PROCEDURE.‍PROVIDED AN ORAL EXPLANATION OF ITS RESPONSES TO CX601 MARKETING AUTHORIZATION​.  Full Article

Tigenix granted orphan drug designation from the U.S. FDA for CX601
Monday, 23 Oct 2017 01:01am EDT 

Oct 23 (Reuters) - Tigenix Nv :Tigenix granted orphan drug designation from the U.S. FDA for cx601.‍exploring expedited pathways to accelerate submission and review process for U.S. Regulatory approval​.  Full Article

TiGenix granted orphan drug designation from FDA for CX601
Monday, 23 Oct 2017 01:00am EDT 

Oct 23 (Reuters) - TIGENIX NV ::REG-TIGENIX GRANTED ORPHAN DRUG DESIGNATION FROM THE U.S. FDA FOR CX601.  Full Article

Tigenix H1 operating loss widens to 20.5 million euros
Tuesday, 19 Sep 2017 01:00am EDT 

Sept 19 (Reuters) - TIGENIX NV ::H1 OPERATING LOSS EUR 20.5 MILLION VERSUS LOSS OF EUR 13.1 MILLION YEAR AGO.H1 LOSS FOR THE PERIOD EUR 26.2 MILLION VERSUS LOSS OF EUR 9.4 MILLION YEAR AGO.H1 TOTAL REVENUE EUR 588,000 VERSUS EUR 943,000 YEAR AGO.STRONG CASH POSITION AT JUNE 30, 2017 OF EUR 56.5 MILLION.EXPECTS EUR 15.0 MILLION MILESTONE POTENTIAL PAYMENT BY TAKEDA ON EU APPROVAL DECISION IN H1 2018.EXPECTS TAKEDA TO LAUNCH CX601 IN EU MARKETS IN H1 2018.EXPECTS CX601 IND AND START OF RECRUITMENT IN U.S. CENTERS INTERIM FINANCIAL STATEMENTS IN H1 2018.EXPECTS CX601 CHMP OPINION IN H2 2017.PLAN ON NEW INDICATIONS FOR CX601 IN H2 2017.  Full Article

Euronext announces quarterly revision of Belgian indices
Thursday, 7 Sep 2017 01:38pm EDT 

Sept 7(Reuters) - Euronext NV ::Announces quarterly review of the BEL 20 .BFX, BEL Mid .BELM and BEL small .BELS indices.TiGenix <<>> to be included in the BEL Mid index.Xior Student Housing <<>> to be included in the BEL Mid index.Balta Group <<>> to be included in the the BEL Small index.Changes will be effective as of Sept 18.  Full Article

Tigenix obtains commercial production license for expanded manufacturing facility
Tuesday, 5 Sep 2017 01:00am EDT 

Sept 5 (Reuters) - TIGENIX NV ::TIGENIX OBTAINS COMMERCIAL PRODUCTION LICENSE FOR EXPANDED MANUFACTURING FACILITY.PROVIDES CAPACITY FOR POTENTIAL EUROPEAN COMMERCIAL ROLL OUT OF INVESTIGATIONAL STEM CELL THERAPY, CX601‍​.EXPANDED FACILITY ALSO SECURES MANUFACTURING FOR OTHER PIPELINE PRODUCTS.‍​.  Full Article

Swissmedic acceptes Takeda and Tigenix's file on Cx601 for review
Tuesday, 20 Jun 2017 01:18am EDT 

June 20 (Reuters) - TIGENIX NV ::TAKEDA <<<4502.T>>> AND TIGENIX ANNOUNCE THAT SWISSMEDIC HAS ACCEPTED FOR REVIEW THE FILE ON CX601 FOR THE TREATMENT OF COMPLEX PERIANAL FISTULAS IN CROHN’S DISEASE PATIENTS.  Full Article

BRIEF-JP Morgan Chase & Co notifies 3.12 pct shareholding in Tigenix​

* ‍JP Morgan Chase & Co notifies 3.12 pct shareholding in Tigenix​ Source text for Eikon: Further company coverage: